This is Part 2 of a two-part Guideline from the European Society of Gastrointestinal
Endoscopy (ESGE) on the endoscopic management of enteral tubes. This part addresses
peri- and post-procedural considerations, including adverse events, as well as modalities
of treatment and prevention.
Abbreviations
AE:
adverse event
BBS:
buried bumper syndrome
CRP:
C-reactive protein
CT:
computed tomography
EN:
enteral nutrition
ESGE:
European Society of Gastrointestinal Endoscopy
ETCO2
:
end-tidal carbon dioxide
ESPEN:
European Society for Clinical Nutrition and Metabolism
D-PEJ:
direct percutaneous endoscopic jejunostomy
GRADE:
Grading of Recommendations Assessment, Development, and Evaluation
HNC:
head and neck cancer
ICU:
intensive care unit
NGT:
nasogastric tube
NJT:
naso-(duodeno)-jejunal tube
OR:
odds ratio
PEG:
percutaneous endoscopic gastrostomy
PEG-J:
percutaneous endoscopic gastrostomy with jejunal extension
PG:
percutaneous gastrostomy
RCT:
randomized controlled trial
1 Introduction
Enteral tube feeding is one of the cornerstones of nutritional support since it allows
the provision of enteral nutrition (EN) in patients who have a functionally normal
digestive tract but cannot meet their nutritional requirements because of inadequate
oral intake [1]. Enteral tube insertion is a major part of the daily activity of an endoscopic unit;
in the UK alone, for example, up to 17 000 percutaneous endoscopic gastrostomies (PEGs)
are placed annually [2]. Nevertheless, procedure-related morbidity and even mortality, remain an important
concern, especially taking into consideration that the patient population involved
is already frail [3]. Furthermore, there are still numerous controversies related to enteral tube insertion.
This evidence-based Guideline was commissioned by the European Society of Gastrointestinal
Endoscopy (ESGE) and aims to address all major issues concerning endoscopic management
of enteral tubes. This is the second of the two parts of the Guideline, and is dedicated
to peri- and post-procedural considerations including adverse events (AEs) and their
management. The first part, published as a separate manuscript [4] focused on definitions, enteral access and tube modalities, and preprocedural considerations,
including preprocedural assessment and indications and contraindications for enteral
tube insertion.
2 Methods
ESGE commissioned this Guideline (ESGE Guidelines Committee chair, J.v.H.) and appointed
a guideline leader (M.A.), who in turn, invited the listed experts to participate
in the project development. The topics and key questions were prepared by the coordinating
team (M.A., P.G.) and then approved by the other members. The key topics consisted
of preprocedural management (including indication/s), preprocedural assessment, periprocedural
technical modalities, and post-procedural management (including AEs). The guideline
development process included meetings and online discussions that took place from
September 2019 to July 2020.
The authors performed a systematic literature search through PubMed/MEDLINE, the Cochrane
Library, and Embase for papers published on this topic up to January 2020. The search
focused on fully published randomized controlled trials (RCTs) and meta-analyses.
Retrospective analyses and case series were also considered for inclusion if they
addressed topics not covered in prospective studies. For important outcomes, papers
were individually assessed using the Grading of Recommendations Assessment, Development,
and Evaluation (GRADE) system for grading of evidence levels and recommendation strengths,
as described in the ESGE guideline development policy [5]. Each author developed draft proposals which were each discussed and debated electronically,
and eventually through a face-to-face meeting held in January 2020 in Brussels, Belgium.
After agreement among the authors on a final version, the manuscript was reviewed
by two experts selected by the ESGE Governing Board and then disseminated to all ESGE-affiliated
societies and individual members. After agreement on a final version, the manuscript
was submitted for publication to the journal Endoscopy. All authors agreed on the final revised manuscript.
This Guideline is issued in 2020 and will be considered for review and update in 2024
or earlier, if new and relevant evidence becomes available. Any updates to the Guideline
in the interim will be noted on the ESGE website: http://www.esge.com/esge-guidelines.html.
3 Periprocedural management: endoscopic techniques for tube insertion
3 Periprocedural management: endoscopic techniques for tube insertion
3.1 Nasojejunal tube (NJT) insertion
ESGE suggests placing an NJT for short-term jejunal access, either through the nostril
with an ultrathin transnasal gastroscope and a guidewire, or through the mouth by
inserting the NJT directly into the biopsy channel of a gastroscope followed by an
oronasal transfer.
Weak recommendation, very low quality evidence.
NJTs can be placed endoscopically using either of two techniques, depending on the
type of tube used. One technique requires endoscopic guidance only. Dedicated narrow-bore
(8- or 10-Fr) NJTs can be inserted directly through the working channel of a gastroscope
or pediatric colonoscope, and positioned beyond the ligament of Treitz [6]. The endoscope is then pulled back while advancing the NJT under direct endoscopic
visualization during withdrawal of the endoscope so that tube coiling is avoided.
An oronasal transfer is then required to pass the NJT through the nose.
Another technique (“over the wire”) involves passage of an ultrathin transnasal gastroscope
through either nostril. A guidewire is then inserted down the biopsy channel of the
ultrathin gastroscope and under direct endoscopic and fluoroscopic guidance; this
is then passed beyond the ligament of Treitz [6]. Once the guidewire is in the desired position, the endoscope is withdrawn, while
simultaneously advancing the guidewire in a “one-to-one fashion,” to maintain its
distal position without looping or coiling. The stomach should be kept decompressed
as the scope is initially passed and also during withdrawal, in order to minimize
gastric volume. Finally, the NJT is threaded over the guidewire and advanced using
a Seldinger technique, while putting slight tension on the guidewire, until it reaches
the jejunum. Clipping of the tip of the NJT to the mucosa has been shown to reduce
displacement [7].
3.2 PEG insertion
ESGE recommends the “pull” technique as the standard method for PEG placement.
Strong recommendation, low quality evidence.
ESGE recommends the direct percutaneous introducer (“push”) technique for PEG placement
in cases where the “pull” method is contraindicated, for example in severe esophageal
stenosis or in patients with head and neck cancer (HNC) or esophageal cancer.
Strong recommendation, low quality evidence.
ESGE recommends percutaneous gastropexy of the anterior gastric wall to the anterior
abdominal wall with T-fasteners or a dedicated suturing device prior to “push” PEG
placement, in order to prevent deflection of the stomach and tube misplacement.
Strong recommendation, low quality evidence.
3.2.1 Overview
In principle, there are two major techniques for PEG tube placement: the peroral “pull”
technique and the direct percutaneous “push” procedure. The success rate of PEG tube
placement is as high as 99.5 % (range 76 % – 100 %). Reasons for failure include inadequate
transillumination, complete oropharyngeal or esophageal obstruction, and previous
gastric resections [8].
The “pull-string” or “pull” method introduced by Gauderer et al. in 1980 has established
itself as the most widely accepted technique for PEG placement in clinical practice
[9]. PEG placement using the “pull” method has replaced surgical gastrostomy [10]
[11] since it is safer and more cost-effective, with lower procedure-related mortality
(0.5 % – 2 %) and complication rates [12]
[13].
The direct percutaneous technique, namely the “introducer” or “push” PEG, using a
balloon-type tube placed transabdominally into the stomach, was first described by
Russell et al. [14] for patients in whom the standard “pull” technique either cannot be used (e. g.
because of presence of an esophageal stricture) or would involve an increased risk
during passage of the internal bumper (e. g. risk of implantation metastasis in malignant
diseases, mainly in primary squamous cell pharyngoesophageal cancer) [15]. The main problem initially associated with this technique was deflection of the
stomach wall during puncture, combined with the risk of tube misplacement. However,
its safety has since been improved through the use of an intragastrically positioned
T-fastener to fix the stomach to the abdominal wall, under fluoroscopic or endoscopic
guidance [16]
[17]. A new, safe-introducer method has also become available recently. This allows the
combination of a double gastropexy with a peel-away trocar-sheath introducer, to effectively
secure the stomach wall to the anterior abdominal wall [18]
[19].
Different types of enteral tubes are placed according to the type of insertion technique:
enteral tubes with an internal bumper are used for the “pull” technique, whereas balloon-type
tubes are used for the “push” technique.
3.2.2 General preparation [20]
-
Patient fasting overnight (6 hours for solids and 2 hours for clear liquids, longer
if there is impaired gastric motility)
-
Antibiotic prophylaxis (single intravenous dose of a beta-lactam antibiotic, or suitable
alternative in case of allergy, according to local policy; see Recommendation, section
3.4)
-
PEG insertion is performed using a strict sterile/aseptic technique (skin disinfection,
sterile surgical drapes, sterile gloves, sterile dressing, etc.)
3.2.3 Description of the “pull” technique [10]
[21]
Two operators are required to insert a PEG tube: the endoscopist and the second operator
who performs abdominal wall puncture and thread/wire traction. An upper gastrointestinal
(GI) endoscopy is performed with the patient in the supine position. During endoscopy,
the stomach is fully insufflated (ideally with carbon dioxide [CO2]) in order to appose the stomach to the abdominal wall and displace any interposed
viscera.
The desired puncture site (on the anterior gastric wall in the region of the distal
corpus) is then identified by means of transillumination and finger indentation (by
the second operator). The second operator then marks the skin over the chosen site,
and after adequate skin cleansing and infiltration with local anesthetic, a green
(21-G) seeker needle, attached to a 10-mL syringe (half-filled with 0.9 % saline)
is inserted vertically through the skin and abdominal wall into the insufflated stomach.
It is important for the second operator to maintain negative pressure on the syringe
plunger as the needle is advanced, and to observe for any gas bubbles, which may be
aspirated into the syringe (needle aspiration technique). Gas bubbles within the syringe
that are seen earlier than when the needle is seen to puncture the gastric wall (on
the endoscopic view) may indicate that an interposed viscus may have been punctured
inadvertently and this should raise concern to seek an alternative site of puncture.
Once the seeker needle is safely in place, the second operator makes an appropriate
incision over this puncture site, and the introducer trocar (and its overlying cannula/sheath)
is then inserted under direct endoscopic visualization with constant endoscopic gaseous
insufflation of the stomach. The dedicated thread/wire (found within the PEG kit)
is then passed through the cannula/sheath and into the stomach by the second operator,
where it is grasped by the endoscopist using a small endoscopic snare or grasping
forceps. Once grasped securely, the thread/wire is then drawn out through the mouth
together with the gastroscope by the endoscopist. The thread/wire loop is then secured
tightly with a simple loop to the corresponding thread/wire loop provided at the external
end of the PEG tube.
The second operator then applies continuous traction to the thread/wire through the
abdominal wall puncture site, and the thread/wire-attached PEG tube is drawn down
the esophagus and stomach and out through the puncture site until the internal fixation
bumper apposes the anterior wall of the stomach. Provided that positioning of the
PEG tube has been conducted without complications, the position of the internal bumper
may be confirmed endoscopically, although this step is optional and not strictly necessary
[22].
3.2.4 Description of the “introducer” or “push” technique (PEG with gastropexy) [18]
[19]
Again, two operators are required for the “push” or “introducer” technique: the endoscopist
and second operator. The procedure is done under strict aseptic/surgical conditions
and local anesthesia. Percutaneous puncture of the stomach is performed through a
previously determined area of the anterior gastric wall, by means of a dedicated double-lumen
or T-fastener gastropexy device under direct endoscopic visualization.
The same steps as the “pull” technique described above are used to identify a safe
and adequate puncture site with a seeker needle and attached syringe. With ongoing
gaseous insufflation of the stomach by the endoscopist, after adequate skin cleansing
and local anesthetic infiltration, the second operator places two or three gastropexies
(in a triangular fashion) at a distance of 20 mm from one another. With maintenance
of full gastric insufflation by the endoscopist, the second operator, securely fastens
the gastropexies and makes a skin incision within the area between the gastropexies.
The second operator then uses the dedicated trocar and overlying peel-away sheath
for puncture of the abdominal wall and anterior gastric wall through the skin incision.
This is done gently and under direct endoscopic visualization and with careful orientation
of the trocar into the gastric lumen, in order to avoid inadvertent laceration/puncture
of the posterior gastric wall. The metal trocar, is then removed, leaving the dedicated
peel-away sheath in situ within the puncture tract.
A balloon-type PEG tube is then introduced through the sheath and once the tube balloon
has been filled with sterile water under endoscopic visualization, the sheath is peeled
away, leaving the tube and fastening external bumper in situ.
3.3 Percutaneous endoscopic gastrostomy with jejunal extension (PEG-J) and direct
percutaneous endoscopic jejunostomy (D-PEJ) insertion
ESGE recommends placement of a jejunal feeding tube either through a PEG-J or D-PEJ
in patients needing long-term EN and through a jejunal route. The choice between PEG-J
and D-PEJ would depend on patient characteristics (anatomy, need for gastric aspiration,
pre-existing PEG), as well as local expertise.
Strong recommendation, low quality evidence.
Long-term jejunal feeding can be achieved endoscopically through jejunal tube extensions
passed through a PEG (PEG-J) or through direct percutaneous endoscopic jejunostomy
(D-PEJ) [23]
[24].
PEG-J placement beyond the ligament of Treitz can be carried out by pushing a jejunal extension feeding
tube through a previously placed PEG using a “beneath the scope” [27] or “over the wire” tube technique, under fluoroscopic guidance [24]
[28]
[29]
[30]
[31]. Extension jejunal tubes are limited to 9 Fr – 12 Fr in diameter, depending on the
size of the previously placed PEG tube; they are approximately 60 cm in length. The
extension tube may be grasped endoscopically with a forceps or a snare and dragged
into the jejunum (“beneath the scope”) or advanced over an endoscopically placed guidewire
or stiffening catheter (“over the wire”).
PEG-J tubes have an initial high success rate of up to 93 % [8]
[20]
[23]
[24]. However, functional success is limited because of frequent retrograde migration
of the jejunal extension tube into the stomach [32] and tube dysfunction caused by kinking or obstruction (as the jejunal tube maximum
diameter is restricted to 12 Fr) [23]
[24]. Endoscopically placed clips may secure the distal end of the tube to reduce the
risk of retrograde migration [33]. Additionally, the initial PEG site should be near the antrum, to create a better
angle of insertion and reduce the distance between the abdominal wall and the pylorus
[6]. Finally, a nonrandomized, comparative study in patients with native gastric anatomy
(56 patients with D-PEJ and 49 with a PEG-J) concluded that feeding tube patency lasted
longer and fewer endoscopic re-interventions were required for patients with D-PEJ
as compared with PEG-J [34].
D-PEJ placement is a modification of the “pull” PEG technique and is usually indicated for long-term
jejunal EN [24]
[35]
[36]
[37]
[38]. For endoscopic visualization a push enteroscopy is performed with a standard or,
preferably, a pediatric colonoscope, or with a dedicated push enteroscope. Some reports
have shown a higher success rate using single-balloon [39] or double-balloon enteroscopy [40].
Once jejunal transillumination and finger indentation are observed on the anterior
abdominal wall (indicating the identification of a favorable superficial jejunal loop),
this is used as an indicator of the scope’s position within the jejunum. In an identical
fashion to that described for the “pull” PEG insertion technique, described above,
after adequate cleansing of the skin and using a strict aseptic technique, a green
(21-G) seeker needle is used for infiltration of local anesthetic by the second operator.
The seeker needle is then used to determine an optimal position prior to the trocar/needle
pass. Grasping the tip of the seeker needle with a snare or a forceps helps to stabilize
the jejunal segment and allows proper orientation for insertion of the larger trocar/needle
alongside the indwelling seeker needle [41]. As described for the “pull” PEG insertion technique, a dedicated thread/wire is
advanced through the plastic sheath by the second operator (after the trocar has been
withdrawn). This thread/wire is then grasped by the awaiting endoscopist using a forceps
or small snare, and the procedure is completed as described for the “pull”-type PEG
placement. Though similar to PEG placement, D-PEJ is a considerably more challenging
technique. In the two largest retrospective cohorts on D-PEJ outcome involving a total
of 738 patients, successful placement was achieved in 68 % – 83 % [35]
[38]; this may be higher if a double-balloon or single-balloon enteroscope is used [39].
The choice between a PEG-J and D-PEJ depends on local expertise, patient anatomy,
pre-existing abdominal surgery, the presence of a pre-existing PEG, the need for concomitant
gastric aspiration (favors the PEG-J), and the risk of retrograde migration of the
jejunal extension (favors D-PEJ) [6].
3.4 Use of prophylactic antibiotic administration before insertion of a percutaneous
tube (PEG/PEG-J/D-PEJ)
ESGE recommends the intravenous administration of a prophylactic single dose of a
beta-lactam antibiotic (or appropriate alternative antibiotic, in the case of allergy)
to decrease the risk of post-procedural wound infection.
Strong recommendation, moderate quality evidence.
A number of RCTs have highlighted the valuable role of preprocedural antibiotic administration
for reduction of peristomal infections [19]
[42]
[43]
[44]
[45]
[46]
[47]
[48]
[49]
[50]
[51]
[52]
[53]
[54]. In the largest of these studies, which compared single-dose intravenous cefuroxime
(750 mg) (n = 50) with placebo (n = 51) given 30 minutes before PEG placement, peristomal
wound infection was significantly reduced during the first week in patients who had
received the antibiotic as compared with the placebo group [48]. Pooled data from one meta-analysis including 10 RCTs (1059 patients), showed that
prophylactic penicillin- or cephalosporin-based treatment decreases the risk of post-procedural
wound infection [55]. The highest relative risk reduction was achieved with administration of penicillin
rather than cephalosporin (13 % vs. 10 %, respectively) [55].
In the most recent Cochrane database systematic review of 12 studies (n = 1271 patients)
comparing intravenous antibiotic administration prior to PEG insertion with placebo,
no intervention, or simple skin antiseptic, a significant benefit for antibiotic administration
was detected (odds ratio [OR] 0.36, 95 %CI 0.26 – 0.50) [56]. The optimal timing of antibiotic administration has not been determined, but based
on the methodology of these studies, intravenous administration 30 minutes before
the procedure appears to be reasonable [57] (Tables 1(a)s, 1(b)s, available online-only in Supplementary material). Nevertheless, in another RCT, a single 20-mL dose of an oral solution of co-trimoxazole
deposited via the PEG catheter immediately after insertion has been shown to be at
least as effective as preprocedural intravenous cefuroxime prophylaxis [43]
[58]. This regimen can be proposed in patients with penicillin-related allergy. Finally,
in patients who are already receiving antibiotics, no specific antibiotic prophylaxis
is required [20].
Further to prophylactic antibiotic administration, the adherence to a full sterile,
aseptic technique and avoidance of excessive pressure between the skin and the external
bumper have also been shown to decrease the risk of wound infection [59].
3.5 Periprocedural adverse events (AEs)
ESGE recommends that periprocedural AEs related to endoscopic placement of any enteral
tube should be considered to also carry the intrinsic risks relating to the sedation/general
anesthesia used.
Strong recommendation, low quality evidence.
ESGE recommends that inadvertent insertion of an NGT into the respiratory tract should
be considered a serious but avoidable AE.
Strong recommendation, low quality evidence.
ESGE recommends that visceral perforation, peritonitis, and bleeding should be considered
as potential periprocedural AEs of PEG, PEG-J, or D-PEJ tube placement.
Strong recommendation, low quality evidence.
Periprocedural AEs are rare and rates should be of the order of < 0.5 % [20]
[60], if strict contraindications are adhered to [20]
[61]
[62].
Sedation/general anesthesia. As with all other endoscopic procedures performed under sedation or general anesthesia,
endoscopic placement of enteral tubes carries cardiovascular and pulmonary risks,
which directly relate to the sedation/anesthetic itself [63]. These include risks of hemodynamic instability, dysrhythmias and aspiration pneumonitis.
The rate of aspiration AEs occurring periprocedurally has been reported to be around
1 %, and risk factors for this include the supine position, type and dose of sedation
used, neurologic impairment, and advanced age [20]
[60].
NGT insertion is mostly performed “blindly” at the patient’s bedside. AEs related to NGT insertion
include epistaxis, coiling of the tube within the esophagus, and most importantly,
inadvertent placement into the respiratory tract [64]
[65]; this occurs infrequently but may potentially have fatal consequences. A retrospective
study reported a 1.3 % incidence (n = 50) of misplacement in over 2000 NGT insertions
in adults over a period of 4 years; mechanical ventilation and altered mental status
appear to be risk factors [66].
NJTs are placed in the endoscopy suite, with or without fluoroscopy. The main periprocedural
complications concerning NJTs relate to incorrect placement, tube kinking, and periprocedural
dislodgment [7]. NJTs with a spiral end to facilitate bedside placement in patients with intact
gastric motility are also available [67].
PEG, PEG-J, and D-PEJ tubes. Periprocedural AEs that are not related to sedation are rare (0.1 %), albeit potentially
serious, and include: perforation of interposed viscera (including the colon, small
bowel, liver, and spleen), peritonitis, and bleeding [20]
[60]
[62].
Although perforation of an interposed viscus is rare, transient subclinical pneumoperitoneum
is a common finding following PEG insertion, occurring in up to 56 % of procedures
and generally not of any clinical significance [68]. Conversely, full-blown peritonitis presents as abdominal pain, leucocytosis, ileus,
and fever. It can result in significant morbidity if not identified and treated early
[20].
Risk factors for bleeding include anticoagulation and previous anatomic alteration
[20]. Immediate gastric bleeding after PEG placement is very rare (0.3 %) and is usually
caused by injury of the left gastric or gastroepiploic arteries or one of their branches
[69]. Severe intraperitoneal bleeding can also occur because of liver laceration and
this presents as severe post-procedural hypotension with or without peritonitis [70]. PEG-J placement poses the additional risk of retrograde migration of the jejunal
extension back into the stomach, and this may lengthen the duration of the procedure
[60]. Finally, D-PEJs have a slightly higher rate of periprocedural AEs, reaching 2 %;
these include bleeding and small-bowel perforation [35]
[38].
3.6 Prevention and management of periprocedural AEs related to enteral tube placement
ESGE recommends careful preprocedural selection, preassessment, and optimization of
any underlying patient comorbidities in order to reduce any sedation/general anesthetic
risks. Should any sedation/general anesthetic periprocedural AEs arise, these should
be managed using specific measures that address the event, with a low threshold to
abandon or postpone the procedure.
Strong recommendation, low quality evidence.
ESGE recommends careful attention to safe procedure technique during PEG, PEG-J, or
D-PEJ placement, in order to reduce the risk of inadvertent injury to any interposed
viscera. In the case of any ongoing concern relating to incorrect placement/perforation,
the patient’s condition should be stabilized and there should be a low threshold to
proceed to urgent, computed tomography (CT) scanning.
Strong recommendation, low quality evidence.
ESGE recommends close monitoring after PEG, PEG-J or D-PEJ tube placement, with due
attention to unexplained tachycardia and hypotension. Should these occur, the patient
should be resuscitated and transferred for urgent CT mesenteric angiography to rule
out any intra-abdominal bleeding.
Strong recommendation, low quality evidence.
ESGE recommends that each institution have a dedicated protocol to confirm correct
positioning of NGTs placed “blindly” at the patient’s bedside, including radiography,
pH testing of the aspirate, and end-tidal carbon dioxide monitoring, but not auscultation
alone.
Strong recommendation, low quality evidence.
ESGE recommends confirmation of correct NGT placement by radiography in high-risk
patients (intensive care unit [ICU] patients or those with altered consciousness or
absent gag reflex).
Strong recommendation, low quality evidence.
Sedation- or general anesthesia-related AEs. In order to reduce any sedation- or general anesthesia-related risk, careful patient
selection should be undertaken. This should include preassessment of the patient and
optimization of their overall condition and underlying comorbidities, which may pose
additional risks [63]
[71]. The use of multidisciplinary nutrition support teams has been shown to be helpful
with patient selection and choice of type of enteral access, and to help reduce overall
AEs [72]. Moreover, the endoscopist can further minimize the risk by avoiding excessive sedation,
aspirating the gastric contents before the procedure, suctioning previously insufflated
gas after the procedure, and by performing the procedure in a time-efficient manner
[20].
Should any sedation/general anesthesia-related AE occur, the procedure should be paused
or abandoned, and specific measures to address the event should be undertaken. Cardiopulmonary
resuscitation equipment and essential drugs (including reversal agents) should be
readily available for immediate use [63].
NGT placement: periprocedural AEs In order to minimize the risk of inadvertent placement into the respiratory tract,
a widely applied technique is to auscultate for sounds of airflow at the end of the
tube or to place the tip into a glass of water to observe for bubbles. However, there
is not always enough air movement to make this a safe strategy to adopt and other
methods to confirm placement are therefore mandatory. Similarly, auscultation methods
are not accurate enough to assess whether the tube is within the lung or the GI tract,
with accuracy rates as low as 34.4 % [73]. The gold standard for confirming correct placement is chest radiography with visualization
of the entire length of the tube according to previous guidelines, ranging from “always
required” to “use when other methods fail” [64]
[74]
[75]
[76].
Additional methods can be used to lower the number of radiographs needed to confirm
correct positioning; these include pH sensors or end-tidal carbon dioxide (ETCO2) monitoring [64]. An aspirate pH of ≤ 5.5 as well as the appearance of the fluid is also commonly
used to confirm that the NGT is correctly positioned within the stomach [64]
[75]. Nevertheless, in a prospective study including 97 and 106 samples taken during
gastroscopy and bronchoscopy, respectively, the sensitivity for correctly identifying
gastric samples at ≤ 5.5 was 68 % and the specificity was 79 % [77]. Although proton pump inhibitors do not seem to be associated with pH > 5, there
was a considerable overlap between esophageal and gastric aspirates, therefore limiting
the differentiation between correct gastric positioning and tube misplacement with
retrograde coiling into the esophagus [78].
ETCO2 monitoring using capnography or colorimetric capnometry has also been used to assess
tube location [64]. A meta-analysis on 456 nasogastric tube insertions, mainly in an ICU setting with
mechanically ventilated patients, revealed a sensitivity ranging from 0.88 to 1.00,
and a specificity from 0.95 to 1.00 [79].
Finally, nose–earlobe–xiphoid distance is frequently used to estimate the insertion
length of nasogastric tubes. Nevertheless, this method has been proven inaccurate,
with underestimation of insertion length in more than 20 % of patients and overestimation
of insertion length in 17.2 % of patients [80]. Underestimating the insertion length may lead to malpositioning of the tube in
the distal esophagus and therefore increase the risk of reflux and pulmonary aspiration.
Marking the tube at the exit site from the nares can serve as an indicator of whether
or not the tube has been partially removed, but this cannot exclude a retrograde migration
of the tip into the esophagus [64].
NJT placement: periprocedural AEs. During endoscopic placement, every effort should be made to pass the tube beyond
the ligament of Treitz, in order to reduce any risk of retrograde dislodgment back
into the stomach. Functional patency of the tube should also be checked after endoscopic
placement by regular assessment of ease of tube-flushing; this allows immediate correct
repositioning and avoidance of any persistent obstructive kinking of the tube.
PEG, PEG-J, and D-PEJ: periprocedural AEs. In order to reduce periprocedural risk in PEG, PEG-J, and D-PEJ placement, in addition
to careful patient selection and review of any pre-procedural cross-sectional imaging
[81], certain technical periprocedural considerations described below, may also help
[20]
[60].
Perforation of an interposed viscus. Preventive maneuvers include: sufficient insufflation of the stomach to enhance its
apposition to the abdominal wall; the achievement of good transillumination; external
finger indentation (as viewed endoscopically); and the use of a green (21-G) seeker
needle attached to a syringe half-filled with saline (the “safe track” technique)
[20]
[60]
[62]. Prior to any attempt at insertion of the trocar, the seeker needle should be used,
with negative pressure applied to the syringe plunger as the seeker needle is advanced
through the skin. Any gas bubbles seen to appear within the syringe before endoscopic
visualization of the seeker needle, may indicate interposition of another viscus (e. g.
the colon or a small-bowel loop) and the targeted area of choice should be changed,
or the procedure abandoned. In the case of any ongoing concern relating to incorrect
placement/perforation, the patient’s condition should be stabilized and there should
be a low threshold to proceeding to urgent CT scanning and involvement of the surgical
team [20].
Bleeding. Despite all precautions and appropriate technique, PEG, PEG-J, and D-PEJ placement
all carry the risk of precipitating significant bleeding. This mainly relates to the
use of the percutaneously inserted trocar/needle, which may inadvertently puncture
large vessels within the abdominal wall, visceral surface/wall, or mesentery. Although
cutaneous and intraluminal bleeding are immediately recognized and may be treated
with external pressure or endotherapy, respectively, intraperitoneal major bleeding
from other injured vessels may remain occult and strict vigilance regarding the patient’s
vital parameters is therefore required, for at least the first 2 hours post-procedure
[3]. Particular attention should be paid to unexplained tachycardia and hypotension.
Should these occur, the patient should be resuscitated and transferred for an urgent
CT mesenteric angiogram to rule out any intra-abdominal hemorrhage.
3.7 Appropriate documentation of endoscopic insertion of enteral tubes
ESGE recommends appropriate documentation regarding endoscopically placed enteral
tubes.
Strong recommendation, low quality evidence.
The procedure report should include the following elements, where applicable: indication
for the procedure; type and dose of sedation/general anesthesia use; type of insertion
technique; the number of attempts/trocar passes; type/gauge/brand of tube used; and
serial number/batch of tube used (with the corresponding traceability sticker placed
in the patient notes). There should also be documentation of antibiotic cover; type
and dose of local anesthetic infiltrated into the skin or abdominal wall; and clear
documentation of the internal bumper-to-skin distance, for reference.
4 Post-procedural management
4 Post-procedural management
4.1 Using the percutaneous enteral tube (PEG, PEG-J, D-PEJ) for the first time after
endoscopic placement
ESGE recommends that EN may be started within 3 to 4 hours after uncomplicated placement
of an PEG or PEG-J.
Strong recommendation, high quality evidence.
ESGE suggests that EN may be started within 24 hours after uncomplicated placement
of a D-PEJ.
Weak recommendation, low quality evidence.
Two meta-analyses, including RCTs with 355 and 467 patients, respectively, showed
no differences in terms of morbidity (local infections, diarrhea, bleeding, fever,
gastroesophageal reflux, vomiting, stomatitis, leakage) or early mortality (< 72 hours)
when feeding was started within 3 to 4 hours from PEG placement as compared with delayed
commencement of EN ( > 24 hours) [82]
[83] (Table 2s). One meta-analysis revealed a statistically significant increase in gastric residual
volume in the case of early feeding (OR 1.80, 95 %CI 1.02 – 3.19; P = 0.04), but without any clinical consequences [82]. Moreover, a prospective comparative study suggested that early feeding after PEG
tube insertion could also help reduce inpatient stay [84]. Finally, in the two largest series of D-PEJ, the initiation of enteral feeding
was reported to be within 4 to 24 hours after placement [35]
[38].
4.2 Post-procedural AEs, mortality, and associated risk factors relating to percutaneous
enteral tube (PEG/PEG-J/D-PEJ) insertion
ESGE recommends cautious preprocedural patient selection since patient characteristics
are related to early and long-term PEG-associated mortality.
Strong recommendation, low quality evidence.
ESGE recommends considering patient age, the presence of stroke as an indication,
and preprocedural nutritional and inflammatory status as risk factors for early and
long-term PEG-related mortality.
Strong recommendation, low quality evidence.
Although PEG placement is considered a safe procedure if all recommended precautions
are applied, post-procedural AEs may still occur. The AE incidence rate ranges from
4.8 % to 26.2 % [85]
[86]
[87], while early (30-day) and 1-year mortality are reported to be of the order of 1.8 % – 23.5 %
[58]
[85]
[87]
[88]
[89]
[90] and 35 % – 55 % [85]
[86]
[90]
[91], respectively. AEs are usually minor with major ones being reported in up to 2 %
of cases [58].
In a retrospective study of more than 400 patients treated by either “pull” or “introducer
or push” PEG, multivariate analysis revealed that underlying malignancy was a predictor
of early (≤ 7 days) complications, while age ≥ 70 years and diabetes mellitus predicted
late (> 7 days) post-procedural AEs [87]. In the same analysis thrombocytopenia (< 100 000/μL) and a high C-reactive protein
(CRP) level (≥ 5 mg/dL) were associated with increased 30-day mortality rate, while
patients suffering from other neurological diseases (apart from stroke) had lower
30-day mortality risk as compared with patients suffering from stroke or underlying
malignancy [87]. Among the 20 patients who died within 30 days following PEG placement, pneumonia
was the most frequently identified cause of death [87].
In a large retrospective study (n = 1625) low serum albumin (< 31.5 g/L) and increased
CRP (> 21.5 mg/L) levels were associated with an increased 30-day mortality, with
patients carrying both factors having an even shorter median survival [92]; similar results were also identified in a prospective, large cohort study [88]. Higher CRP levels were found to be the only independent risk factor for 30-day
mortality in another study from Portugal (n = 157); the definitive cutoff value was
a CRP level of ≥ 35.9 mg/dL [93].
As mentioned above, stroke patients appear to have worse survival and this was confirmed
in another retrospective study of 500 patients [90]. In this cohort of patients with neurological disease, the median survival was shorter
in patients who were suffering from stroke (11.4 vs. 27.1 months, P = 0.014). Moreover, in the subgroup of stroke patients, multivariate analysis identified
preprocedural neutrophil percentage and late AE as negative independent prognostic
factors, while prophylactic antibiotic usage and hyperlipidemia were found to be inversely
correlated to mortality [90]. Similarly, in another cohort (n = 100), patients undergoing PEG placement because
of underlying neurologic disease had a significantly higher 6-month mortality as compared
with patients treated for underlying malignancy (60 % vs. 27.7 %, P = 0.002) [86].
In a recent study from Israel (n = 272) multivariate analysis identified older age,
higher creatinine levels and elevated CRP-to-albumin ratio as significant predictors
of short-term mortality after PEG placement [89]. Finally, in two further recent large studies, from Italy and Sweden (n = 950 and
n = 495, respectively), age and lower body mass index (BMI) were identified as risk
factors for mortality [58]
[85] (Table 3s).
4.3 Post-procedural AEs related to enteral tube insertion
ESGE recommends considering wound infection, buried bumper syndrome, peristomal leakage,
tube dislodgment, and fistula formation as the main post-procedural complications
related to PEG/PEG-J/D-PEJ.
Strong recommendation, low quality evidence.
Several post-procedural PEG AEs have been described in detail elsewhere [4]
[60]
[62]. They include infection-related AEs, namely wound infection and necrotizing fasciitis;
complications related to dysfunction of the enteral access tract, namely buried bumper
syndrome (BBS); peristomal leakage; PEG site herniation; tube dislodgment; gastric
outlet obstruction; and fistula formation.
4.3.1 Wound infection
ESGE recommends local antiseptic measures and daily dressing changes for minor (nonextending)
wound infections and broad-spectrum antibiotics for more severe infections.
Strong recommendation, low quality evidence.
Infectious complications are considered to be the most common PEG-associated AEs [94]
[95]. In the era of prophylactic antibiotic use, the incidence of infection has decreased
significantly [58]
[85], albeit this remains high, especially in developing countries [96]. Infections are usually mild and limited to the peristomal PEG site, but less frequently,
more serious infectious complications including abscess formation and necrotizing
fasciitis may occur [3]. In the case of local wound infection, the clinical examination reveals a painful
PEG site with erythema, induration and potential purulent exudate with or without
signs of systemic inflammation. Mild peristomal erythema is commonly found and should
not be considered as an infection.
For mild wound infection, treatment consists of local antiseptic measures and regular
dressing changes. Broad-spectrum antibiotics should be administered, either orally
if the diagnosis is made early after PEG placement (within 3 – 5 days) or intravenously
in cases of later diagnosis or in those with a more severe presentation (e. g. systemic
sepsis); antibiotic therapy should be guided by sample culture and sensitivity results.
Surgical intervention is reserved for severe complications, including abscesses, peritonitis,
or necrotizing fasciitis; the last-mentioned is a rare but potentially fatal AE after
PEG insertion, that requires both antibiotic coverage and appropriate surgical debridement
of the infected area [97]
[98].
4.3.2 Buried bumper syndrome (BBS)
ESGE recommends that daily tube mobilization (pushing inward) along with a loose position
of the external PEG bumper (1 – 2 cm from the abdominal wall) could mitigate the risk
of buried bumper syndrome (BBS) development.
Strong recommendation, low quality evidence.
BBS refers to the migration of the internal PEG bumper along the PEG tract, ending
up within the gastric or abdominal wall with consequent overgrowth of gastric mucosa
over the bumper [99]. It occurs in 1 % – 4 % of cases [85]
[100]. BBS is caused by excessive traction between the internal PEG bumper and the abdominal
wall that results in local pressure necrosis and subsequent migration [101]. This traction is the result of excessive, usually long-term, PEG tightening post-placement;
other associated, potentially contributory factors include obesity, weight gain, and
chronic cough [102].
BBS is diagnosed clinically by visualization and palpation of the subcutaneously located
bumper, and by endoscopic or CT demonstration of the migrated internal bumper. Pain
at the PEG site, loss of tube patency, and leakage around the PEG site are other common
findings in patients with BBS. BBS may lead to other complications such as bleeding,
peritonitis, and abscess formation [100]
[103].
In cases of incomplete BBS, where part of the internal bumper is still visible and
the tube remains patent, the buried bumper can be effectively pushed back into the
stomach by using a dilator [104] or the push – pull T technique [105]
[106]. In cases of complete BBS, endoscopically guided application of electrosurgical
incisions using a sphincterotome, a needle-knife, or recently developed dedicated
devices can be used [104]
[107]
[108]
[109]. For complicated extragastric cases [110] or when endoscopy fails to release the trapped bumper, surgery remains an option.
If indicated, a new PEG should be placed a couple of weeks later, at a different site,
in order to allow adequate healing of the previous tract. However, cases of simultaneous
insertion of a new balloon-type tube have also been described [111]
[112].
Initial (3 – 5 days after insertion) tighter fixing of the abdominal wall bolster
and the internal bumper, aimed to prevent leakage, should be followed by a looser
position of the external skin bumper with a 1 – 2 cm distance from the abdominal wall,
in order to mitigate the risk of BBS [103]. Appropriate daily care, tube mobilization (pushing inward), and placement of a
gauze pad under the external bolster could also reduce the risk of BBS development
[59]. Rotation of the tube should be avoided in cases of PEG-J and D-PEJ in order to
avoid jejunal extension dislodgment and jejunal volvulus, respectively [35]
[36].
4.3.3 PEG site herniation
PEG site herniation is a rare complication associated with PEG placement [113]
[114]
[115]
[116]
[117]
[118]. It presents with ongoing leakage, bulging, or pain at the PEG site, either while
the tube remains in situ or when it is removed. Choosing the optimal site for PEG
placement and, if possible, avoiding the weakest points of the abdominal wall (e. g.
the linea alba/midline) may reduce the risk of herniation. Appropriate surgical management
of the hernia may be required.
4.3.4 Peristomal leakage
ESGE suggests that an effort to treat any underlying predisposing disease should be
made in the case of peristomal leakage. Local treatment with absorbing agents, stoma
adhesive powder, and zinc oxide may reduce local skin irritation.
Weak recommendation, low quality of evidence.
ESGE suggests, that in the case of persistent leakage, the PEG tube should be removed
and a new PEG should be placed at a different site.
Weak recommendation, low quality of evidence.
Peristomal leakage of gastric content may occur in up to 2 % of cases following PEG
placement [119]. Usually this appears early after PEG insertion but delayed leakage may also occur
[94]. Different risk factors have been identified. Among them, local factors include
skin infection, excessive cleaning with abrasive products, increased gastric acid
secretion, gastroparesis, side torsion of the tube, BBS, increased tension between
internal and external bumpers, and presence of granulomatous tissue within the tract.
Systemic conditions such as diabetes mellitus, immunodeficiency, or severe malnutrition,
which prevent adequate wound healing [95]
[120], are also associated with peristomal leakage.
Optimal management of peristomal leakage includes treatment of any underlying predisposing
disease and local treatment with absorbing agents. Antisecretory medication and prokinetics
can also be used to reduce gastric acidity and stasis. The use of stoma adhesive powders
or zinc oxide application has been proposed to reduce local skin irritation [20], while topical application of silver nitrate or argon plasma can be used in the
case of a coexisting granuloma [62]. For persisting delayed peristomal leakage EN should be interrupted, and the tube
should either be removed temporarily (24 to 48 hours) to permit partial closure, using
a guidewire to secure tract patency, or there should be complete removal of the tube
and replacement at another site of the abdominal wall, once the previous tract has
healed completely [59]
[120]. In the case of delayed gastric emptying despite prokinetics, a PEG-J or D-PEJ may
be considered. For balloon-type tubes with peristomal leakage, it should always be
verified that the balloon is adequately inflated.
4.3.5 Tube dislodgment
ESGE recommends that in the case of early ( < 4 weeks) tube dislodgment, “blind” tube
reinsertion should be avoided. The patient should be monitored clinically and broad-spectrum
antibiotics should be administered in symptomatic patients. A new PEG should be placed
once the initial tract has healed.
Strong recommendation, low quality evidence.
ESGE recommends that in the case of late (> 4 weeks) tube dislodgment, a bedside balloon-type
replacement tube, if available, can be immediately placed through the established
tract. Otherwise, a Foley catheter can be used to maintain the tract as a temporary
bridge to PEG tube replacement.
Strong recommendation, low quality evidence.
Tube dislodgment is considered to be a frequent PEG-associated AE. The incidence ranges
from 13 % to 29 % [85]
[121]
[122]; apart from the association with major complications, tube dislodgment also results
in significant healthcare costs [123].
In the vast majority of cases, tube dislodgment occurs towards the exterior of the
abdominal wall, either by inappropriate manipulation of the tube or by accidental
pulling, especially in patients with altered mental status or cognitive impairment.
Management of outer tube dislodgment depends on the time that it occurs, since the
PEG tract is expected to mature within 4 weeks from placement [1]. Therefore, if dislodgment occurs after 4 weeks from initial placement, one can
consider that the tract is mature and if a replacement balloon-type tube is available
on site, this can be inserted through the pre-existing tract at the patient’s bedside,
without recourse to endoscopic visualization. If a replacement is not available and
since the mature tract will start closing within the first 24 hours from tube dislodgment,
the insertion of a temporary Foley catheter, in an attempt to keep the mature tract
patent has been proposed [124]
[125]. However, the use of Foley catheters has been associated with high complication
rates [125] and the evidence to recommend their use is considered to be of low quality [126]. In the case that replacement tube position is uncertain, direct endoscopic verification
or use of a water-soluble contrast facilitated “tubogram” should be used to confirm
the position.
In the case of tube dislodgment within the first 4 weeks of its insertion, there is
a risk of gastric content leakage and consequent peritonitis, since the stomach may
separate from the abdominal wall. In that case, “blind” tube replacement should be
avoided, since it could lead to tube malposition in the peritoneal cavity. The patient
should be kept nil-by-mouth, and broad-spectrum antibiotics should be administered.
An attempt to place a new PEG tube at a different site of the abdominal wall may be
performed, once the initial tract has healed [124].
Infrequently, a patient may present with abdominal pain and vomiting, as the result
of gastric outflow obstruction from a distally dislodged PEG tube, causing post-pyloric
blockage by the internal bumper or balloon. Clinical suspicion of internal migration,
usually raised by the inappropriate position of the external bumper, can be confirmed
endoscopically or radiologically. This event can easily be reversed by simply pulling
the PEG tube back (after deflating the balloon in the case of a balloon-type tube)
and fixing its external bumper in the correct position [127].
Various methods have been proposed to prevent tube dislodgment; these include sophisticated
tube designs such as low profile “button-type” tubes [128]
[129]. In a recent RCT, balloon-tube dislodgment was significantly less frequent in a
group of patients who underwent weekly measurement of the water volume within the
balloon followed by tube replacement at 3-monthly intervals [130]. Cost concerns and tube-type selection would however hinder the general applicability
of this strategy.
4.3.6 Gastrocolocutaneous fistula
This is a rare AE that occurs when the colon is accidentally punctured during PEG
or D-PEJ placement. Its occurrence creates a fistulous tract through the gastric wall,
colon, abdominal wall and finally the skin [131]. Its clinical appearance varies from asymptomatic to fecal leakage around the PEG
site, frank perforation, or colonic obstruction. More often it usually becomes symptomatic
once the initially placed tube is removed or replaced by another tube, the distal
end of which is wrongly positioned within the transverse colon. In this case the patient
presents with diarrhea once the enteral feeding is re-initiated [132]. Contrast-mediated radiographic imaging facilitates accurate diagnosis. The treatment
of choice consists of PEG tube removal to allow the fistulous tract to heal. If this
is unsuccessful, an endoscopic approach, using over-the-scope clips or full-thickness
transmural sutures, or surgery (especially for persistent or complicated cases) have
also been used [133]
[134]
[135]
[136].
4.3.7 Gastrocutaneous fistula, after PEG removal
ESGE recommends endoscopic modalities as the first-line management in the case of
persisting gastrocutaneous fistula after PEG removal.
Strong recommendation, low quality evidence.
Healing of the gastrocutaneous tract usually starts within 24 hours of PEG removal
and is often complete within a few days. In a limited number of cases it takes weeks
for the tract to heal. However, in some cases the tract fails to heal and a gastrocutaneous
fistula persists. Studies in children showed that a gastrocutaneous fistula developed
in 1 out of 4 patients; longer PEG duration was associated with a higher likelihood
of fistula formation [137]
[138].
The presence of a fistulous tract is easily recognized by presence of persistent or
periodic leakage of gastric fluid from the previous PEG site on the skin of the abdominal
wall. Currently, different endoscopic modalities, mainly consisting of the use of
through-the-scope or over-the-scope clips, as well as application of argon plasma
coagulation and endoscopy-assisted suturing, offer promising results and have obviated
the need for surgical intervention in most cases [133]
[139]
[140]
[141]
[142]
[143]
[144]
[145].
4.4 Post-placement instructions to carers for enteral tube maintenance
ESGE suggests daily care of the PEG/PEG-J/D-PEJ site using a sterile saline solution
and dressing application for the first week after placement. Loosening of the internal
bumper after 3 to 5 days is suggested, and mobilization of the tube should begin from
7 to 10 days after placement.
Weak recommendation, low quality evidence.
After the percutaneous tube placement, the skin and the position of the tube should
be checked every day. The external fixator should be placed tightly, 0.5 cm above
the skin, to prevent leakage during the first 3 to 5 days [146]. During the first week, the peristomal skin must be kept clean with a sterile saline
solution, which is then dried. Before handling, manual hygiene and the use of gloves
is important to prevent infection. A dressing may be applied to absorb any potential
exudate, but it is not considered mandatory [147]. In that regard, a sterile “Y”-shaped dressing should be placed under the external
site and the disc plate to reduce the tension applied. Any dressings must be changed
regularly. Occlusive dressing use is not recommended, because of an increased risk
of skin maceration. Glycerin hydrogel wound dressing can be used as an alternative,
since it has been associated with significantly reduced rate of peristomal infections
during the first 2 weeks post-PEG placement [148]; if used, this should be changed once per week.
At 3 to 5 days after insertion, the external bumper can be loosened by up to 1 cm.
Only after 7 to 10 days should the tube be gently moved from 2 to 5 cm inward and
outward in order to prevent future adhesion and BBS [146]. After this maneuver, the tube should be returned to and fixed in its initial position;
the distance between the exit point of the tube and the abdominal wall should be marked
with a permanent marker [146]. As already discussed in the cases of D-PEJ and PEG-J, any rotation of such tubes
should be avoided [149], since this could lead to jejunal volvulus (D-PEJ) or displacement of the jejunal
extension (PEG-J) [35]
[36]. This is generalized to all percutaneous tubes in order to standardize the protocol
of care independently of the type of enteral access used. After a gastropexy (“introducer”
or “push” technique), the tube should be mobilized once the gastropexy tags have been
removed (generally after 2 to 4 weeks).
After 7 to 10 days, the peristomal skin should be cleaned with soap and fresh tap
water and then dried, twice a week. Patients are allowed to bathe, shower, and swim
with a waterproof dressing thereafter [1].
4.5 Administration of medications through an enteral tube
ESGE suggests that the use of medication in liquid form is preferred; if crushed solid
forms are administered through enteral tubes, these should be optimally flushed through,
in order to avoid tube occlusion.
Weak recommendation, low quality evidence.
Medication administration through an enteral tube requires careful evaluation. Not
all drugs are safe for enteral administration. Drug – nutrient or drug – drug interactions
can impact efficacy and increase toxicity [75]. Tube size and placement site should be considered before the introduction of a
medication. Narrow-bore tubes (< 12-Fr; 1 Fr = 0.33 mm)] are more comfortable but
increase the risk of clogging [75]. An incorrect administration method could also lead to tube obstruction. The placement
site of the tube may also affect drug absorption; the majority of drugs are absorbed
within the small intestine but some are absorbed within the stomach. For medications
with a high first-pass hepatic metabolism, jejunal access could increase their absorption
and consequently, their systemic effects [150]. The administration process should also take into account the timing of drug delivery
with respect to flushing protocols, administration of other medications, and the enteral
nutrition regimen [75]. In this regard, an integrated training program for nurses delivered by a clinical
pharmacist has been shown to significantly improve drug administration via enteral
feeding tubes [151].
Drug dose adjustment may be required and liquid formulations are preferred, in order
to prevent tube occlusion. Diluted liquid medication can help reduce osmolality shifts
and enhance drug delivery rates. If specific liquid medication is unavailable or inappropriate,
a solid formulation may have to be used. Tablets may be crushed to a powder for suspension
and hard gelatin capsules may be opened and mixed with purified water. Distinct syringes
(the recognized standard, ISO 80369-3 for enteral tubes [“ENFit”]) should be used
when administering drugs through an enteral tube, in order to avoid accidental parenteral
injection. Appropriate irrigation of the enteral tube is mandatory before any drug
administration. The tube should be flushed with 30 mL of water [1]. The flush is repeated between medications and after the last administration. Enteral
nutrition should be stopped 30 minutes before drug administration and may be restarted
30 to 60 minutes after [146]. In the case of a drug–nutrient interaction, enteral nutrition should be discontinued
for 2 hours before drug administration.
4.6 Enteral tube replacement
ESGE recommends PEG tube replacement in the case of tube fracture, dislodgment, degradation,
persisting peristomal wound infection/leakage, or skin ulceration.
Strong recommendation, low quality evidence.
ESGE recommends against routine replacement of PEG tubes with internal bumpers.
Strong recommendation, low quality evidence.
ESGE recommends replacement of balloon-type PEG tubes at 3- to 6-month intervals,
or according to brand instructions, to prevent balloon failure.
Strong recommendation, low quality evidence.
There is no optimal evidence-based guideline regarding the replacement of non-balloon
and balloon-type PEG tubes; however, there are several recommendations which can be
divided into those concerning scheduled or unscheduled replacements. Indications for
unscheduled replacement are catheter breakage, occlusions that cannot be resolved
conservatively, dislodgment, or dysfunction. In addition, persisting peristomal infection/leakage
after appropriate antibiotic treatment, fungal colonization with material deterioration,
and non-healing skin ulceration despite optimal wound care, may also be indications
to remove and/or replace the tube [1]
[75]
[152].
Scheduled replacements are dependent on the internal fixation type of the enteral
tube. PEG tubes with internal bumpers are long-lasting; up to 70 % can stay in place
for more than 2 years [20]
[153] and do not require scheduled replacement. Conversely, for balloon-type tubes, it
is recommended to develop local protocols that reflect manufacturer guidelines, as
balloon failure can occur and lead to tube dislodgment. Most balloon-type tubes have
to be replaced regularly at 3- to 6-month intervals [20]
[130].
The balloon is deflated and retrieved, and a new balloon-type tube is inserted and
inflated with sterile water (not saline) according to specifications (usually 5 to
10 mL) [62]. Water volume may be checked every week to prevent spontaneous balloon deflation
because of water leakage [1].
Dislodged PEG tubes often demand emergency consultations in a frail patient population
and should be managed appropriately as soon as possible [154].
4.7 Definitive enteral tube removal
ESGE recommends against removing a percutaneous enteral tube within 4 weeks of insertion.
Strong recommendation, low quality evidence.
ESGE suggests using the “cut and push” technique for removing enteral tubes with internal
bumpers. However, in patients with previous bowel surgery, strictures, or ileus, endoscopic
removal of the internal bumper is suggested.
Weak recommendation, low quality evidence.
When a percutaneous enteral tube (PEG/PEG-J/D-PEJ) is no longer required, it should
be removed. However, before removal, it is advisable to ensure that the patient is
able to keep a stable weight for a couple of weeks, without EN support [1]. Furthermore, it usually takes up to 4 weeks after insertion for a percutaneous
tract to mature, or even longer in frail patients with significant comorbidities [1]. Therefore, a percutaneous enteral tube should not be removed within 4 weeks of
insertion, in order to avoid the risk of internal leakage and peritonitis.
For a bumper-type tube, removal is performed by cutting the tube at the abdominal
skin level and pushing the internal bumper into the intestinal lumen with a blunt
stylet (“cut and push” technique) [155]
[156]. This is particularly useful for patients with a D-PEJ, in whom endoscopic retrieval
can be particularly challenging and invasive [36]. Endoscopic retrieval of the bumper is recommended in cases with previous bowel
surgery and for patients at risk of strictures or ileus, which could hinder spontaneous
migration and elimination of the tube remnant and bumper [1]
[157]
[158].
4.8 Optimal outpatient care for patients with enteral tubes
ESGE recommends that patients with enteral tubes are regularly monitored by a dedicated
multidisciplinary team (in collaboration with home caregivers, nurses, and general
practitioners), for efficacy of EN support and for potential complications.
Strong recommendation, low quality evidence.
Despite the overall positive effect of home enteral nutrition, tube-related complications
are frequent and can lead to a hospital readmission rate as high as 23 % at 6 months
[159]. A small prospective study of 8 patients with home enteral nutrition showed that,
despite systematic monthly follow-up by a dedicated nurse, there was an average of
5.4 unscheduled healthcare contacts over 10.5 months, mostly for tube-related complications
[160]. Therefore, monitoring after discharge should include not only surveillance of efficacy
regarding enteral nutrition administration (weight, nutritional parameters, muscle
strength, food intake), but also of tolerance (digestive tolerance, tube-related complications)
[1]. The modalities of outpatient monitoring depend upon patient-related factors (underlying
disease, nutritional status on discharge, active treatment or palliative care), and
structure-related factors (home care or institution) [1]. In any case, communication between the in-hospital prescribing multidisciplinary
nutrition team and the home or institution caregivers, as well as adequate training
of the caregivers are crucial elements to assure optimal management.
In a prospective study involving 313 patients with PEG who were followed up by a dedicated
team, 371 complications were encountered. Through this collaborative approach, most
of these were resolved without recourse to hospitalization, resulting in a significant
reduction of PEG-related hospital readmissions to 2 % (P < 0.0001) [159]. These encouraging results were echoed by the findings of an multicenter observational
study from Poland, where collaborative care by a dedicated team was shown to reduce
overall morbidity and costs relating to long-term home enteral nutrition [161].
Disclaimer
The legal disclaimer for ESGE guidelines [5] applies to this Guideline.